Background Infliximab is a chimeric monoclonal antibody against tumour necrosis factor‐
alpha for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Recently, a …

Background Efficacy and safety of new subcutaneous (SC) formulation of CT-P13 (CT-P13
SC) up to Week 30 were comparable with intravenous (IV) formulation in both patients with …

Background Two randomised controlled trials of a novel subcutaneous (SC) formulation of
infliximab in patients with active rheumatoid arthritis1 and in patients with active Crohn's …

Background & aims This study compared pharmacokinetics, symptomatic and endoscopic
efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab …

The new subcutaneous (sc) formulation of the infliximab (IFX) biosimilar CT‐P13 results in
homogeneous serum trough concentrations of IFX at steady state. The present study aimed …

Abstract Background and Aims: Biosimilar infliximab CT-P13 is approved for all indications
of the originator product in Europe. Prospective data on its efficacy, safety, and …

Background: Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative
colitis, is characterized by chronic relapsing intestinal inflammation. There are few data on …

Introduction Biologic drugs have significantly improved the treatment of ulcerative colitis
(UC) and Crohn's disease (CD). However, the availability of these drugs is limited by their …

CT-P13 is the first subcutaneous infliximab molecule approved for the management of
inflammatory bowel disease (IBD). Compared to intravenous therapy, SC infliximab offers a …

Abstract Background and Aim The biosimilar of infliximab, CT‐P13, has recently been
shown to be equivalent to infliximab in both efficacy and safety in the treatment of …